Inhaled diabetes drug developer MannKind hopes to raise as much as $110 million by lending 9 million shares of its stock to Merrill Lynch, a Bank of America holding, at $5.55 a share. Merrill Lynch will then short the stock, giving MannKind additional funding support R&D costs, and for general corporate purposes. MannKind's stock dipped on news of the stock sale. Article